Published in J Invest Dermatol on August 01, 1998
The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol (2002) 1.13
Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol (2009) 1.09
Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun (2000) 1.01
Evaluation of a novel non-penetrating electrode for use in DNA vaccination. PLoS One (2011) 0.96
Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J (2010) 0.89
Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules. J Pharm Sci (2010) 0.85
Single systemic administration of Ag85B of mycobacteria DNA inhibits allergic airway inflammation in a mouse model of asthma. J Asthma Allergy (2012) 0.80
DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev (2014) 0.79
Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES. J Biomed Sci (2012) 0.78
Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol (2000) 0.77
Comparative analysis of macrophage associated vectors for use in genetic vaccine. Genet Vaccines Ther (2011) 0.77
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67
DNA-based immunization by in vivo transfection of dendritic cells. Nat Med (1996) 3.62
NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol (1987) 3.06
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun (1990) 1.70
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood (2001) 1.47
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med (1996) 1.32
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol (1995) 1.26
Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol (1995) 1.25
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol (2000) 1.20
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol (1998) 1.16
FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol (1997) 1.12
Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol (2000) 1.12
Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol (2001) 1.08
Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther (2000) 1.08
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res (1996) 1.05
Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells (1997) 1.04
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res (1999) 1.03
Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J Invest Dermatol (1997) 1.02
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ (2007) 1.02
Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol (1994) 1.00
Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther (1994) 1.00
Analysis of antigen presentation by metabolically inactive accessory cells and their isolated membranes. Proc Natl Acad Sci U S A (1985) 0.98
Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother (1995) 0.98
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A (1999) 0.98
Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci (1996) 0.98
Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol (2008) 0.98
A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology (1999) 0.96
Phospholipase treatment of accessory cells that have been exposed to antigen selectively inhibits antigen-specific Ia-restricted, but not allospecific, stimulation of T lymphocytes. Proc Natl Acad Sci U S A (1986) 0.96
Treatment of pyogenic granulomas with the 585 nm pulsed dye laser. J Am Acad Dermatol (1996) 0.95
HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol (1999) 0.95
Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother (1998) 0.94
Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Mol Ther (2001) 0.92
Characterization of antigen association with accessory cells: specific removal of processed antigens from the cell surface by phospholipases. Proc Natl Acad Sci U S A (1987) 0.92
Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphasis Tumor Immunol (1993) 0.91
Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother (2001) 0.91
Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol (1999) 0.90
Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J Gene Med (2001) 0.90
Direct transfection and activation of human cutaneous dendritic cells. Gene Ther (2001) 0.90
Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol (1997) 0.90
Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol (1996) 0.90
Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther (2009) 0.89
Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther (1999) 0.88
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res (1996) 0.88
Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun (1995) 0.87
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther (2006) 0.87
EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. Am J Transplant (2007) 0.87
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol (1996) 0.87
Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol (1999) 0.87
Dendritic cell based therapy of cancer. Adv Exp Med Biol (1997) 0.86
B cell sensitivity to natural killing: correlation with target cell stage of differentiation and state of activation. J Immunol (1986) 0.86
Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther (2007) 0.86
IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther (1995) 0.85
Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol (2007) 0.84
'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Ther (2005) 0.83
Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol (2000) 0.82
Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther (2011) 0.82
IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci (1996) 0.81
Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther (2009) 0.81
Gene-based strategies for the immunotherapy of cancer. J Mol Med (Berl) (1997) 0.81
Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res (1995) 0.81
Oxygen-reactive metabolites are not detected at the effector-target interface during natural killing. J Leukoc Biol (1986) 0.81
Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin Cancer Res (1996) 0.81
Novel approach to gene expression profiling in Sézary syndrome. Br J Dermatol (2010) 0.79
Quantitation and sorting of vitally stained natural killer cell-target cell conjugates by dual beam flow cytometry. Cytometry (1986) 0.79
Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther (2013) 0.79
Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci (1996) 0.78
TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol Today (1995) 0.78
Expression and function of the costimulatory molecule B7 on murine Langerhans cells: evidence for an alternative CTLA-4 ligand. Eur J Immunol (1994) 0.77
DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv Exp Med Biol (1998) 0.77
Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplant Proc (2001) 0.77
Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am (2006) 0.76
Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Eur J Immunol (1996) 0.76
Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitors. J Immunol (2001) 0.76
Giving DNA vaccines a helping hand. Nat Med (1998) 0.75
Generating and regulating immune responses through cutaneous gene delivery. Hum Gene Ther (2000) 0.75
The immunology of DNA vaccines. Methods Mol Med (2000) 0.75
Development of dendritic cell-based genetic vaccines for cancer. Adv Exp Med Biol (1997) 0.75
Effects of in vivo monoclonal anti-I-A antibody treatment in neonatal mice on intrathymic and peripheral class II antigen expression. Cell Immunol (1988) 0.75